Patients with clinical Stage IB–IIA cancer of the uterine cervix treated by radical hysterectomy ,  bilateral pelvic lymphadenectomy ,  and aortic lymph node sampling were eligible for entry into this prospective study if they had one or more of the following risk factors ,  (1) metastatic disease to pelvic lymph nodes ,  (2) large primary tumors greater than or equal to 4 cm in diameter ,  (3) deeply invasive lesions with 75% or greater stromal invasion ,  (4) nonsquamous histology ,  and/or (5) occult parametrial involvement or positive surgical margins .
There were 12 major protocol viola-patients received only a portion of the proscribed treatment ,  tions ,  including 7 patients who were randomized (6 to che-one patient ,  randomized to chemotherapy ,  withdrew after chemotherapy plus radiation therapy and 1 patient to chemother-experiencing an allergic bleomycin reaction during the initial chemotherapy alone) and then either refused treatment (n ?6) or were infusion of bleomycin during cycle 1 .
Four patients randomized to chemotherapy plus radiation refused either the radia-to follow-up or had no follow-up data available for analysis.  tion therapy (n ?3) or had a major violation in the radiation Thus ,  there were 33 patients who received the combination therapy treatment plan when intravaginal radiation therapy of chemotherapy and pelvic radiation and 39 who received was administered ,  and she did not receive the last 2 cycles chemotherapy alone who could be evaluated for disease-of cisplatin (n ?1). free and overall survival .
Major toxicity suggest that a 65% 5-year survival rate after therapy combinincluded one patient who did not receive the second cycle ing radical hysterectomy ,  pelvic lymphadenectomy ,  and of bleomycin due to the onset of pulmonary symptoms and postoperative pelvic radiotherapy for patients with pelvic a significant decrease in pulmonary function compared to a lymph node metastases is an improvement compared to his-pretreatment study .
